Nanostructured Lipid Carriers Loaded with Donepezil for Nose-to-Brain Targeting
Pharmaceutics · 28.04.2026 · 18 (5) · 541
DOI: 10.3390/pharmaceutics18050541 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 28.04.2026. Verfasst von Isabelly Fernanda Ferraz de Souza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil (CAPES), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil.
Abstract (Originalsprache)
Background/Objectives: The oral administration of donepezil has been shown to have common side effects due to systemic drug delivery, with fluctuations in blood and brain donepezil concentrations. Therefore, we obtained nanostructured lipid carriers loaded with donepezil (donepezil–NLC) for nose-to-brain targeting.
Methods
The obtained NLCs were characterized by measurements of particle size, the polydispersity index, zeta potential, encapsulation efficiency, atomic force microscopy, Differential Scanning Calorimetry, Fourier transform infrared spectroscopy, X-ray diffraction, and in vitro release studies. Plasma and brain pharmacokinetic studies in Wistar rats were carried out to determine brain targeting.
Results
Donepezil–NLC showed low polydispersity and nanometric size, high zeta potential, and high drug entrapment efficiency. Microscopy images showed spherical particles with regular surfaces. Thermal analysis, X-ray diffraction, and FTIR-ATR suggested the formation of an amorphous lipid matrix and the incorporation of donepezil molecularly dispersed within the lipid matrix. In vitro drug release studies demonstrated a biphasic drug release pattern with an initial burst followed by sustained release, with results better fitted to the Korsmeyer–Peppas model (n-value > 0.5). Following the nasal administration of donepezil–NLC, brain pharmacokinetic studies in Wistar rats demonstrated a significant improvement in bioavailability. Compared to the intravenous injection of donepezil, the AUC0–ꝏ value was 10.5-fold higher. Drug targeting efficiency and direct transport percentage showed extremely higher values, suggesting nose-to-brain targeting after donepezil–NLC intranasal administration.
Conclusions
Donepezil–NLC has proven to be an efficient drug delivery system for the nose to the brain, which may reduce systemic toxicity and improve Alzheimer’s therapy with low doses of donepezil and fewer adverse effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Sciences, Federal University of Alfenas, Alfenas 37130-001, MG, Brazil.
- Pharmacy School, Federal University of Ouro Preto, Ouro Preto 35400-000, MG, Brazil.
ORCID-Profile: Rudy Bonfilio, Vanessa Bergamin Boralli, André Luís Morais Ruela
Förderung
- the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil (CAPES)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil
Zitieren
APA
Souza, I. F. F., Placido, R. V., Placido, M. J., Rocha, L. C., Bonfilio, R., Boralli, V. B., Ruela, A. L. M., & Pereira, G. R. (2026). Nanostructured Lipid Carriers Loaded with Donepezil for Nose-to-Brain Targeting. Pharmaceutics, 18(5), 541. https://doi.org/10.3390/pharmaceutics18050541
Vancouver
Souza IFF, Placido RV, Placido MJ, Rocha LC, Bonfilio R, Boralli VB, et al. Nanostructured Lipid Carriers Loaded with Donepezil for Nose-to-Brain Targeting. Pharmaceutics. 2026;18(5):541. doi:10.3390/pharmaceutics18050541
BibTeX
@article{Souza2026,
author = {Souza, Isabelly Fernanda Ferraz de and Placido, Rodrigo Vicentino and Placido, Maria Júlia and Rocha, Letícia Carvalho and Bonfilio, Rudy and Boralli, Vanessa Bergamin and Ruela, André Luís Morais and Pereira, Gislaine Ribeiro},
title = {Nanostructured Lipid Carriers Loaded with Donepezil for Nose-to-Brain Targeting},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {541},
doi = {10.3390/pharmaceutics18050541}
}
EUVIMED